The News Review:

- PG diploma in clinical trial management
- Encorium Group Appoints Biopharmaceutical Industry Veteran Linda…
- Memory Pharmaceuticals Appoints Paul Blake to Board of Directors.
- GlaxoSmithKline Initiates Trials f Promacta®/Revolade¢ (eltrombopag)…

PG diploma in clinical trial management
Hindu – Nov 12, 2007
Experts have predicted that for the year 2010 the turnover for the industry will be $1 billion to five billion. The industry will require anywhere between 20000 and 50000 trained professionals by 2010. Understanding the demand and industry requirements Bilcare Research a service provider to pharmaceutical companies has announced the launch of Bilcare Research Academy in Bangalore where it will offer a Post-Graduate Diploma in Clinical Trial Management in association with the Association of Clinical Research Professionals. This would be the first ACRP-accredited body in the Asian region.

Encorium Group Appoints Biopharmaceutical Industry Veteran Linda…
Free with registration – Business Wire – AccessMyLibrary.com – Nov 12, 2007
as Chief perating fficer. — Encorium Group Inc. (Nasdaq: ENC) a full service multinational contract research organization (CR) conducting studies in over.

Memory Pharmaceuticals Appoints Paul Blake to Board of Directors.
Free with registration – PR Newswire – AccessMyLibrary.com – Nov 12, 2007
a bio-pharmaceutical company. Blake was Senior Vice President Clinical Research and Development for Avigenics Inc. From 2001 to 2006 Dr. Blake was with Cephalon Inc. in the clinical research and regulatory affairs group most recently as Executive Vice President Worldwide Medical.

GlaxoSmithKline Initiates Trials f Promacta®/Revolade¢ (eltrombopag)…
Medical News Today – Medical News Today (press release) – Nov 12, 2007
Mild to moderate cases may resolve spontaneously without treatment however severe thrombocytopenia can be associated with significant morbidity and mortality. [2][8] The cause of thrombocytopenia associated with hepatitis C is multi-factorial: inadequate thrombopoietin production by damaged liver bone marrow suppression by interferon or viruses (HCV) sequestration of platelets in the spleen and increased platelet destruction from an associated autoimmune process. About Eltrombopag Eltrombopag is an oral non-peptide thrombopoietin receptor agonist that has been shown in pre-clinical research and clinical trials to stimulate the proliferation and differentiation of megakaryocytes the bone marrow cells that give rise to blood platelets and thus can be considered a platelet growth factor. The safety profile will be further examined in ongoing clinical trials. Eltrombopag was discovered as a result of research collaboration between GlaxoSmithKline and Ligand Pharmaceuticals. It is being developed by GlaxoSmithKline. Eltrombopag is an investigational compound that has not received regulatory approval in any market for any indication at this time.